Citation Tools

Download PDFPDF

Original research
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

Download to a citation manager

Cite this article as:
Zhang F, Zheng J, Li Y, et al
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years